Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months

Gould, Jon C.; Garren, Michael; Starling, James R.

doi:10.1016/j.gassur.2004.09.042

Cited by 32 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 Comorbidity reductions are reflected in diminished drug use during the postoperative period, and discontinuation of drug therapy for some diseases, thus resulting in reduced expenditure on drugs and other healthcare services. 10,[14][15][16][17][18] In addition, bariatric surgery extends survival, decreases occurrences of cardiovascular events and is also associated with greater reduction of mortality due to cardiovascular diseases, myocardial infarction, stroke, diabetes and cancer, in comparison with obese individuals who do not undergo this surgery. 10,19,20 The reduction in the risk of myocardial infarction, stroke and adverse cardiovascular events is approximately 50% after this surgery, in comparison with individuals who did not undergo the procedure.…”

Section: Introductionmentioning

confidence: 99%

Medication and nutritional supplement use before and after bariatric surgery

Backes

Lopes²,

Tetelbom

et al. 2016

Sao Paulo Med. J.

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Bariatric surgery has been an effective alternative treatment for morbid obesity and has resulted in decreased mortality, better control over comorbidities and reduced use of drugs. The objective of this study was to analyze the impact of bariatric surgery on medication drug and nutritional supplement use. DESIGN AND SETTING: Longitudinal study of before-and-after type, on 69 morbidly obese patients in a public hospital in Porto Alegre. METHODS: Through interviews, the presence of comorbidities and use of drugs with and without prescription were evaluated. RESULTS: Among the 69 patients interviewed, 85.5% had comorbidities in the preoperative period, with an average of 2.3 (± 1.5) per patient. The main comorbidities reported were hypertension, diabetes and dyslipidemia. 84.1% of the patients were using prescribed drugs in the preoperative period. The mean drug use per patient was 4.8, which decreased to 4.4 after the procedure. The surgery enabled significant reduction in use of most antidiabetic (84%), antilipemic (77%) and antihypertensive drugs (49.5%). On the other hand, there was a significant increase in use of multivitamins and drugs for disorders of the gastrointestinal tract. The dosages of most of the drugs that continued to be prescribed after surgery were decreased, but not significantly. CONCLUSION: After bariatric surgery, there were increases in the use of vitamins, gastric antisecretory drugs and antianemic drugs. Nevertheless, there was an overall reduction in drug use during this period, caused by suspension of drugs or dose reduction. RESUMO CONTEXTO E OBJETIVO:A cirurgia bariátrica tem sido uma alternativa efetiva de tratamento para a obesidade mórbida, resultando na diminuição da mortalidade, melhor controle das comorbidades e redução no uso de medicamentos. O objetivo deste estudo foi analisar o impacto da cirurgia bariátrica sobre a utilização de medicamentos e suplementos nutricionais. TIPO DE ESTUDO E LOCAL: Estudo longitudinal do tipo antes e depois com 69 pacientes obesos mórbi-dos em um hospital público de Porto Alegre. MÉTODOS: Nas entrevistas, foram avaliados a presença de comorbidades e o uso de medicamentos com e sem prescrição médica. RESULTADOS: De 69 pacientes entrevistados, 85,5% apresentaram comorbidades no período pré-cirúrgi-co, média de 2,3 (± 1,5) por paciente. As principais comorbidades relatadas foram hipertensão, diabetes e dislipidemias. 84,1% dos pacientes estavam em uso de medicamentos sob prescrição médica, no período pré-cirúrgico. A média de uso de medicamentos por paciente foi de 4,8, reduzindo para 4,4 após o procedimento. A cirurgia proporcionou diminuição significativa do uso da maioria dos antidiabéticos (84%), antilipêmicos (77%) e anti-hipertensivos (49,5%). Por outro lado, observou-se aumento significativo na utilização de multivitamínicos e medicamentos para desordens do trato gastrointestinal. A maior parte dos medicamentos que continuaram sendo prescritos após a cirurgia teve sua dose reduzida, no entanto, esta redução nã...

show abstract

Section: Introductionmentioning

confidence: 99%

Medication and nutritional supplement use before and after bariatric surgery

Backes

Lopes²,

Tetelbom

et al. 2016

Sao Paulo Med. J.

View full text Add to dashboard Cite

show abstract

“…Additionally, there remains a reluctance of employeebased healthcare systems to make employees aware of the added benefit of bariatric surgery. Such reluctance seems incomprehensible given the marked health benefits and cost savings of the surgery [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] and its uniqueness in providing cost return in as little as two post-operative years [16].…”

Section: Discussionmentioning

confidence: 99%

“…Pharmaceutical savings occur within the first post-operative month and average $160 to greater than $300 per month for an annual cost savings of $2,000 or more [9][10][11][12][13]. In addition to medications, hospitalization costs are significantly reduced by bariatric procedures [5,7,[14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Utilization Rate of Bariatric Surgery in an Employee-Based Healthcare System Following Surgery Coverage

2010

View full text Add to dashboard Cite

Incidence rates for obesity co-morbidities are high for individuals with class III morbid obesity. Bariatric surgery resolves/improves these co-morbidities, along with reduction in healthcare costs. Despite surgery benefits, payors are reluctant to provide coverage for fear of increased demand and costs. This study examines surgery utilization rates following coverage by an employee-based healthcare system. Bariatric surgery utilization rates were measured 1 year before and after healthcare coverage. The data show before coverage that 18 persons had bariatric surgery for a utilization rate of 1.71%. In the year after surgery, 16 persons elected to have bariatric surgery for a utilization rate of 1.42%. These findings should help to dispel the notion by employee-based insurers that coverage of bariatric surgery will lead to high utilization and associated costs in the early-coverage period.

show abstract

“…In addition to being a viable option for weight loss and weight maintenance in patients with morbid obesity [3], bariatric surgeries significantly improved comorbidities and even their regression [9]. Such improvements are reflected in the diminished or discontinued drug use during the post-operative period and consequently reduced expenditure on drug use and other healthcare services [10,11]. Furthermore, bariatric surgeries are associated with reduced overall mortality, mortality due to cardiovascular diseases and the occurrence of cardiovascular events [12,13].…”

Section: Introductionmentioning

confidence: 99%